Search

Displaying results 2811 - 2820 of 8575 in total
  1. Drug

    Sodium copper chlorophyllin

    go.drugbank.com/drugs/DB16522
    Investigational

    This compound is used as a food colorant and supplement[A227718]. … Sodium copper chlorophyllin (SCC) is a water-soluble and bright green mixture derived from natural chlorophyll that has potential antimutagenic and antioxidant properties[A227718].

  2. Drug

    Cabazitaxel

    go.drugbank.com/drugs/DB06772
    ApprovedInvestigational

    It was first approved by the FDA on June 17, 2010.[A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376] … [A260621] As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death.

  3. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    [A239249] Surgical interventions such as partial external bile diversion and ileal exclusion have also been used as treatments. … It was granted FDA approval on 29 September 2021.

  4. Drug

    Raxtozinameran

    go.drugbank.com/drugs/DB18228
    ApprovedInvestigational

    Raxtozinameran is also known as Pfizer-BioNTech COVID-19 Vaccine and Comirnaty. … [A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272]

  5. Drug

    Lobeline

    go.drugbank.com/drugs/DB05137
    Investigational

    An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. … It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]

  6. Drug

    Sepiapterin

    go.drugbank.com/drugs/DB16326
    ApprovedInvestigational

    [L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria.

  7. Drug

    Sacrosidase

    go.drugbank.com/drugs/DB06760
    Approved

    Sacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issue...

  8. Drug

    Doxapram

    go.drugbank.com/drugs/DB00561
    ApprovedInvestigationalVet approved

    A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)

  9. Drug

    Recombinant stabilized RSV A prefusion F antigen

    go.drugbank.com/drugs/DB18713
    ApprovedInvestigational

    [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of

  10. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    Initially, it was marketed in 1995 under the trade name, _Landel_. The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. … It has also been studied in atherosclerosis and acute renal failure [A32001]. This drug is also known as NZ-105, and several studies have been done on its pharmacokinetics in animals [L1456].